hVIVOLSE:HVO -1.45% Median PS Value is £0.12 as of Jun. 30, 2026, which is 100% below its 10-year median of 1.24. The stock has 6 warning signs investors should review. Among 86 Medical Diagnostics & Research companies, hVIVO ranks better than 74.42% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. hVIVO's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £0.068. hVIVO's 10-Year median PS Ratio is 1.7647. Therefore, the Median PS Value for today is £0.12.
As of today (2026-06-30), hVIVO's share price is £0.068. hVIVO's Median PS Value is £0.12. Therefore, hVIVO's Price to Median PS Value for today is 0.57.
The historical rank and industry rank for hVIVO's Median PS Value or its related term are showing as below:
LSE:HVO'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53 Med: 1.24 Max: 1.7
Current: 0.57
During the past 13 years, the highest Price to Median PS Value of hVIVO was 1.70. The lowest was 0.53. And the median was 1.24.
LSE:HVO's Price-to-Median-PS-Value is ranked better than 74.42% of 86
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.895
vs LSE:HVO: 0.57
hVIVO (LSE:HVO) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
hVIVO's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.068
/
0.12
=
0.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
hVIVO Median PS Value Related Terms
hVIVO Median PS Value Historical Data
* Premium members only.
The historical data trend for hVIVO's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:HVO vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, hVIVO's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where hVIVO's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.7647.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. hVIVO's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £0.068.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
hVIVO (LSE:HVO) has a Median PS Value of £0.12 as of Jun. 30, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on hVIVO and its competitors. This is 90% below median its historical median of 1.24. Over the past decade, hVIVO's Median PS Value has ranged from 0.53 to 1.70. According to the industry distribution chart, hVIVO ranks #22 out of 86 companies in the Medical Diagnostics & Research industry, placing it in the top 25.6%.
Is hVIVO's Median PS Value too high?
hVIVO's current Median PS Value of £0.12 is 90% below median its 10-year median of 1.24. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 1.70. Based on the distribution chart, hVIVO ranks #22 out of 86 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does hVIVO's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #22 out of 86 companies for Median PS Value. This puts hVIVO in the upper half of its industry. The industry median Median PS Value is 0.90. Historically, hVIVO's own Median PS Value has ranged from 0.53 to 1.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.90, based on 86 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on hVIVO and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. hVIVO's current Median PS Value is £0.12, which is 90% below median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (LSE:HVO) is currently considered Possible Value Trap. The stock's GF Value™ is £0.16, compared to a current price of £0.07 — trading 57.5% below its estimated fair value. The current Median PS Value is £0.12, which is 90% below median its 10-year median of 1.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For hVIVO (LSE:HVO), the current Median PS Value is £0.12 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:HVO has been successfully added to your 